ChiCTR-OIN-17010698Active, not recruitingPhase 2
TACE 联合血管内皮抑素治疗原发性肝癌疗效与安全性研究
福建省肿瘤转化医学重点实验室1 site in 1 country164 target enrollmentStarted: March 1, 2017Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 164
- Locations
- 1
- Primary Endpoint
- 生存期
Study Overview
Brief Summary
TACE 联合血管内皮抑素治疗原发性肝癌疗效与安全性
Study Design
- Study Type
- 观察性研究
- Primary Purpose
- 非随机对照试验
Eligibility Criteria
- Ages
- 18 to 75 (—)
- Sex
- All
Inclusion Criteria
- •1.BCLC B 或 BCLC C 期肝癌
- •2.Chid - pugh A 或 B 级
Exclusion Criteria
- •门脉主干癌栓或下腔静脉癌栓
Arms & Interventions
2 组
重组人血管内皮抑素
Outcomes
Primary Outcomes
生存期
Time Frame: 入组开始
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
请填写干预措施中，英文全称。 应用 DEB-TACE 对比 cTACE 治疗初治的原发性肝癌患者的疗效和安全性观察ChiCTR2100050928中国健康促进基金会82
Unknown
Not Applicable
TACE 联合阿帕替尼治疗原发性肝癌的前瞻性随机对照临床研究ChiCTR1800019743自筹经费40
Recruiting
Phase 4
卡瑞利珠单抗联合抗血管生成药及 TACE 新辅助治疗临界可切除肝癌的临床研究肝癌ChiCTR210004346220
Unknown
Not Applicable
精细化 DEB-TACE 治疗原发性肝癌的疗效及安全性研究ChiCTR2500106566自筹113
Unknown
Not Applicable
不同载体 DEB-TACE 治疗原发性肝细胞癌的比较原发性肝细胞癌ChiCTR2100044528自筹经费90